Yale Cancer Center carefully invests funds to launch new areas of cancer research. Current funding opportunities are listed below.

2018 Robin Roberts Cancer Survivorship Research Fund 

NOMINATION LIMITATION

The Yale Cancer Center may nominate ONE candidate 


AWARD AMOUNT

This is a three-year grant of $200,000 per year. A maximum of 10% indirect costs (within the award amount) are supported in the Award. NIH salary caps are observed. Grant start date is December 2018


ELIGIBILITY

The nominated applicant must lead the research team. The applicant must meet all of the following criteria to be eligible to submit an application: 

  • By September 17, 2018, the applicant must hold a tenure-track faculty position. Non-promotable, adjunct, affiliated, temporary, part-time or acting faculty positions are not eligible for nomination to lead the research team. 
  • Applicants from US institutions must be either US Citizens or have a legal permit to work in the USA (either temporary or permanent).


IMPORTANT DATES

Internal Deadline: Monday, August 6, 2018 (11:59pm EST) via https://yalecancercenter.submittable.com/submit

Sponsor’s Deadline: Monday, September 17, 2018 (5pm EST)


SCOPE OF RESEARCH 

The V Foundation seeks to support research into the biological basis of and prevention of long-term adverse effects (such as premature death, second neoplasms, organ dysfunction (e.g., cardiac, pulmonary, gonadal, neuropathy), reduced growth and development, decreased fertility, impaired cognitive function) from both conventional therapies including XRT, surgery and targeted therapies, as well as newer immunotherapies. As immune-based therapies become more common, research is also needed regarding infectious disease complications. 

Research areas may apply to adult and/or pediatric populations; to conventional therapies and/or immune-oncology therapies. 

Some research possibilities within this scope could include: 

  • Determine risk stratification models for selection of primary cancer therapy in order to balance efficacy with short and long-term toxicity. Such models may include clinical presentation, tumor features such as histology, stage and genomics and serum biomarkers. Biomarker research in both tumor and “host” are encouraged. 
  • Develop effective targeted intervention strategies to decrease the risk of long-term adverse effects. For example: -Investigate the causal pathway of selected chemotherapeutic agents that cause endothelial dysfunction and accelerate the atherosclerotic process. - Investigate the association between muscle mass loss and cardiometabolic dysfunction among cancer survivors. 
  • Investigate the role of genetic susceptibility in the development of non-malignant treatment related adverse outcomes (in addition to subsequent malignancies) in cancer survivors. 
  • Research to advance early detection of recurrent or secondary cancers using innovative approaches. 
  • When applicable, mining of existing research databases (e.g., GDC, TCIA, TCGA ) containing genomic data, clinical trial data or other for various translational research projects is encouraged to further research to prevent adverse treatment effects for oncology patients (adult or pediatric) post- treatment. This could lead to risk prediction models for adverse treatment effects that would include host and tumor characteristics. 

Note: At this time we will not be funding psycho-social services type research such as quality of life, psychosocial well-being and dysfunction.


INTERNAL COMPETITION REQUIREMENTS

  • A brief description of your proposed research project (two-page maximum). Applications should be 11-pt Arial, Helvetica, or TNR font; margins no less than 0.5 inch all around. Literature citations do not count against this page limit.
  • NIH Biosketch


Further information may be obtained from joann.sweasy@yale.edu or christine.holmberg@yale.edu